Table 1 Patient characteristics at randomization
| Â | Rosuvastatin 10 mg/day | Rosuvastatin 2.5 mg/day Ezetimibe 10 mg/day | P |
|---|---|---|---|
|  | (n = 24) | (n = 22) |  |
Age (y) | 71.8 ± 8.2 | 70.1 ± 9.6 | 0.54 |
Body mass index (kg/m2) | 26.0 ± 2.8 | 24.4 ± 3.2 | 0.08 |
Male, n (%) | 15 (62.5) | 14 (63.6) | 0.94 |
Current or former smoker, n (%) | 15 (62.5) | 11 (50.0) | 0.73 |
Hypertension, n (%) | 19 (79.0) | 17 (77.0) | 0.88 |
Diabetes mellitus, n (%) | 10 (41.7) | 8 (36.4) | 0.71 |
History of MI, n (%) | 13 (54.2) | 11 (50.0) | 0.53 |
Medication | Â | Â | Â |
 Beta-blockers, n (%) | 11 (45.8) | 10 (45.5) | 1.00 |
 ACEIs or ARBs | 19 (79.2) | 17 (77.3) | 0.88 |
 Calcium channel blockers, n (%) | 15 (62.5) | 8 (36.4) | 0.08 |
 Oral hypoglycaemics, n (%) | 9 (37.5) | 8 (36.4) | 0.94 |
 Insulin, n (%) | 4 (16.7) | 1 (4.5) | 0.19 |
 Aspirin, n (%) | 24 (100) | 22 (100) | 1.00 |
 Clopidogrel, n (%) | 18 (75.0) | 13 (59.1) | 0.25 |
Laboratory data | Â | Â | Â |
T-Cho (mg/dL) | 168.0 ± 17.4 | 164.0 ± 23.3 | 0.51 |
LDL-C (mg/dL) | 88.5 ± 12.9 | 84.3 ± 14.5 | 0.30 |
HDL-C (mg/dL) | 46.4 ± 11.6 | 49.9 ± 12.2 | 0.33 |
TG (mg/dL) | 165.4 ± 78.9 | 149.4 ± 103.9 | 0.56 |
LDL-C/HDL-C ratio | 1.96 ± 0.50 | 1.77 ± 0.41 | 0.18 |
MDA-LDL (U/L) | 104.6 ± 26.8 | 94.2 ± 18.8 | 0.14 |
hs-CRP (mg/L) | 2.0 ± 2.0 | 2.5 ± 2.5 | 0.32 |
IL-6 (pg/mL) | 9.4 ± 25.9 | 5.4 ± 6.8 | 0.37 |
TNF-α (pg/mL) | 4.4 ± 8.9 | 7.6 ± 13.9 | 0.37 |
PTX3 (ng/mL) | 1.95 ± 1.23 | 2.02 ± 0.79 | 0.30 |